Standalone and Consolidated Financial Results for 3rd quarter and nine months ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Makers Laboratories reported standalone Q3 FY26 revenue from operations of Rs 1,270.49 lakhs, up about 34% from Rs 945.09 lakhs a year ago. Nine-month standalone revenue rose to Rs 3,907.27 lakhs from Rs 3,324.39 lakhs (around 18% growth). On a consolidated basis, Q3 revenue jumped nearly 29% YoY to Rs 3,566.76 lakhs, driven largely by the Chemical Manufacturing subsidiary, while nine-month consolidated revenue grew around 21% to Rs 10,484.31 lakhs. Standalone results, however, remained in the red with a Q3 loss of Rs 17.22 lakhs and a nine-month loss of Rs 75.61 lakhs (versus a Rs 604.29 lakh profit last year, which included a one-time Rs 1,010 lakh gain from sale of property). Consolidated nine-month PAT stood at Rs 749.07 lakhs, broadly flat versus Rs 753.60 lakhs in the prior year. The statutory auditor issued an unmodified limited review report.
Revenue momentum is healthy, especially at the consolidated level, but the core standalone pharma business continues to post losses despite top-line growth. Overall profitability is being propped up by the chemical manufacturing subsidiary, so investors should watch segment-level trends and whether standalone margins turn positive.